The vaginal yeast infections treatment market is projected to grow from USD 4.4 billion in 2026 to USD 7.7 billion by 2036, at a CAGR of 5.7%. Azole antifungals will dominate with a 56.0% market share, while prescription will lead the applications segment with a 54.0% share.